

17 October 2017

SUCCESSFUL COMPLETION OF ENTITLEMENT OFFER

Analytica Limited (Company) is pleased to announce completion of its 1 for 8 Entitlement Offer (Entitlement Offer).

The Entitlement Offer opened on Tuesday, 26 September 2017 and closed at 5:00pm (Sydney time) on Thursday, 12 October 2017.

The total number of new shares offered under the Entitlement Offer was 318,641,324. The Entitlement Offer has been very well supported by shareholders, with shareholders applying for 266,839,671 shares raising approximately \$1,334,198. Accordingly, the shortfall was 51,801,653 shares.

Directors of the Company, Dr Michael Monsour and Dr Peter Corr, directly and through their related entities, took up their full entitlements under the Entitlement Offer.

Under the terms of the Entitlement Offer 266,839,671 options expiring 31 January 2018 will be issued and 266,839,671 options expiring 31 May 2018 will also be issued (Attaching Options).

The new shares and Attaching Options to be issued under the Entitlement Offer are expected to be issued on Thursday, 19 October 2017, with normal trading of new shares to commence on Friday, 20 October 2017.

Directors would like to thank the shareholders who participated in the Entitlement Offer.

Bryan Dulhunty
Company Secretary

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.

